Abstract
PurposeThe aim of the study was to evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for pulmonary lesions in oligometastatic non‐small cell lung cancer (NSCLC) patients, to explore prognostic factors of progression‐free survival (PFS) and overall survival (OS), to validate improved survival contributed by SBRT in oligometastatic NSCLC patients.Patients and methodsA total of 71 oligometastatic NSCLC patients with 86 pulmonary lesions treated with SBRT in our institute between 2012 and 2018 were included. Local control (LC), progression‐free survival (PFS), and overall survival (OS) were calculated using Kaplan‐Meier method. Prognostic factors of PFS and OS were analyzed using univariate and multivariate Cox analyses. Subgroup analyses were performed to investigate the impact of SBRT on PFS and OS during first line systemic treatment.ResultsAfter a median follow‐up of 17.6 months, 2‐year LC and OS rates were 82.6% and 55.3%, respectively. No grade 4 or more toxicities were observed. Multivariate analysis showed systemic treatment regimen before SBRT was an independent prognostic factor of PFS, but not for OS. Among this cohort, patients receiving first line target therapy could show a better PFS and OS than those undergoing first line chemotherapy (target therapy vs chemotherapy, PFS, 26.4 m vs 6.9 m; OS, 34.8 m vs 15.5 m).ConclusionsSBRT for pulmonary lesions was a feasible and tolerable option for oligometastatic NSCLC patients. Delivery of SBRT for pulmonary lesions improved outcomes of oligometastatic NSCLC patients. Finally, SBRT combined with first line target therapy might have optimal outcomes.
Highlights
The standard therapy for patients with metastatic non‐small cell lung cancer (NSCLC) was systemic treatment with palliative intent, and the role of local treatment remains controversial.[1]
Primary tumor histology, and time interval between systemic treatment and stereotactic body radiotherapy (SBRT) initiation significantly influenced progression‐free survival (PFS) (P < 0.05) (Table 3). Other factors such as gender, smoking, number of metastases, CEA level before SBRT, lesion size were not found to be prognostic for PFS
NSCLC patients with oligometastases treated with surgical resection suggested a more durable disease control.[19,20]
Summary
The standard therapy for patients with metastatic non‐small cell lung cancer (NSCLC) was systemic treatment with palliative intent, and the role of local treatment remains controversial.[1] Oligometastases, which was established by Hellman and Weichselbaum in 1995, is an intermediate state between locoregional tumor spread and disseminated metastases.[2] Oligometastases defined as limited metastases (≤5) reflects a moderate risk of distant metastasis, which could benefit from local therapy.[3,4,5,6] retrospective studies of pulmonary and hepatic metastasectomy from different primary tumors showed a 5‐year survival of 20%‐47%.7-12. Rare studies report the efficacy and safety of SBRT treating for pulmonary lesions of oligometastatic NSCLC patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
